Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Market to Register Stunning Growth During the Forecast Period (2022-2032) - DelveInsight | Key Companies - Innoviva (sulbactam-durlobactam), Aridis, Bioversys, Merck, Polyphor, Omni

As per DelveInsight, the Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Market is anticipated to evolve immensely in the coming years owing to the increased incidence of HABP/VABP and the expected launch of various emerging therapies in the market.

Various therapies such as AR-301, AR-320, AR-101 (Aridis Pharmaceuticals), BV100 (Bioversys), OMN6 (Omnix Medical), SUL-DUR (Entasis Therapeutics), and RG6006 (Abx MCP/RO7223280) (Roche) etc. are being developed which shall fuel the future growth of the market.

DelveInsight's "Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the HABP/VABP Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The HABP/VABP market report covers emerging drugs, treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia (HABP/VABP): An Overview
Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) are the most common infections in hospitalized patients, particularly those in the intensive care units. They are associated with high mortality, economic costs, and antibacterial drug resistance.

Bacterial Pneumonia is frequently categorized based on the site of acquisition. Hospital-acquired (or nosocomial) pneumonia is pneumonia that occurs 48 hours or more after admission and did not appear to be incubating at the time of admission. While ventilator-associated pneumonia is a type of HABP that develops more than 48 hours after endotracheal intubation.

The mortality associated with hospital-acquired pneumonia is high, despite the availability of effective antibiotics. The various therapies approved by the US FDA for the treatment of HABP/VABP include Merck's ZERBAXA and RECARBRIO, Shionogi's FETROJA, Melinta Therapeutics' VABOMERE, Cumberland Pharmaceuticals' VIBATIV, and AbbVie's/ Pfizer's AVYCAZ/ ZAVICEFTA. However, there is still a need for therapies that address the increasing antimicrobial resistance and are effective treatments against a wide spectrum of bacteria.

Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Market Key Facts
• According to a retrospective large-scale Japanese claim database-based study by Kimata et al. (2021), most HABP episodes (77.6%) occurred more than 5 days after hospitalization. During the 12-month pre-index period including outpatients, 84.9% of patients had some type of pneumonia record, 9.1% had VABP, and 7.4% had anti-MRSA prescription records.
• According to a study by Kalanuria et al. (2014), VABP is estimated to occur in 9-27 % of all mechanically ventilated patients, with the highest risk being early in the course of hospitalization. It is the second most common nosocomial infection in the ICU and the most common in mechanically ventilated patients.

Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted HABP/VABP market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the HABP/VABP market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia Market will Grow by 2032:
https://www.delveinsight.com/report-store/hospital-acquired-and-ventilator-associated-bacterial-pneumonia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Epidemiology
The epidemiology section covers detailed insights into the historical and current HABP/VABP patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Epidemiology Segmented as -
• Total Incident Cases of Bacterial Pneumonia in the 7MM [2019-2032]
• Total Incident Cases of HABP/VABP in the 7MM[2019-2032]
• Etiology-specific Cases of HABP/VABP in the 7MM [2019-2032]
• Treated Cases of HABP/VABP in the 7MM [2019-2032]

Get Key Insights Into the Evolving Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia Epidemiology Trends:
https://www.delveinsight.com/report-store/hospital-acquired-and-ventilator-associated-bacterial-pneumonia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the HABP/VABP market or expected to be launched during the study period. The analysis covers HABP/VABP market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the HABP/VABP Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/sample-request/hospital-acquired-and-ventilator-associated-bacterial-pneumonia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Latest Key Developments in the HABP/VABP Therapeutics Market:
On April 17, 2023, Innoviva, Inc. (Nasdaq: INVA) (Innoviva) announced that the US FDA Antimicrobial Drugs Advisory Committee (AMDAC) unanimously voted 12-0 in support of approval based on a favorable benefit-risk assessment of sulbactam-durlobactam for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter). The sulbactam-durlobactam New Drug Application (NDA), filed by Entasis Therapeutics Inc., a wholly owned subsidiary of Innoviva, was accepted and granted Priority Review by the FDA in November 2022, with a Prescription Drug User Fee Act (PDUFA) target action date of May 29, 2023.

Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Therapeutics Assessment
The future of HABP management is likely to be dominated by the reality of increasing antimicrobial resistance. Resistance spreads for a number of reasons, with the overuse of antibiotics and sharing of DNA between organisms being among the important drivers. Many new therapies are in the pipeline for the treatment of HABP/VABP.

Companies across the globe have shifted their focus to the development of drugs to cure diseases caused by different causative agents. To name a few of these: Basilea Pharmaceutica, Merck, Cubist Pharmaceuticals, Shionogi, Pfizer, Aridis Pharmaceuticals, Polyphor, Arsanis, Motif Bio, and others are actively working in the HABP/VABP Therapeutics market. While a few of the aforementioned companies have either entered or are on the verge of completing the Phase III stage of clinical development, yet others, have recently initiated the evaluation of their products in the Phase II clinical development stage.

The Key Companies in the HABP/VABP Therapeutics Market Include:
• Aridis Pharmaceuticals
• Basilea
• Bioversys
• Entasis Therapeutics
• Merck
• Omnix Medical
• Pfizer
• Polyphor
• Roche
• Shionogi
And Many Others

HABP/VABP Therapies Covered in the Report Include:
• AR-301, AR-320, AR-101: Aridis Pharmaceuticals
• BV100: Bioversys
• MK-1986: Merck
• MK-7625A: Merck
• Murepavadin: Polyphor
• OMN6: Omnix Medical
• PF06947387: Pfizer
• RG6006 (Abx MCP/RO7223280): Roche
• S-649266: Shionogi
• SUL-DUR: Entasis Therapeutics
• Zevtera: Basilea
And Many More

Learn More About the Emerging Therapies & Key Companies in the Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia Therapeutics Market:
https://www.delveinsight.com/sample-request/hospital-acquired-and-ventilator-associated-bacterial-pneumonia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia Competitive Intelligence Analysis
4. Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia Market Overview at a Glance
5. Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia Background and Overview
6. Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia Patient Journey
7. Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia Epidemiology and Patient Population
8. Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia Treatment Algorithm, Current Treatment, and Medical Practices
9. Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia Unmet Needs
10. Key Endpoints of Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia Treatment
11. Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia Marketed Products
12. Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia Emerging Therapies
13. Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia Seven Major Market Analysis
14. Attribute Analysis
15. Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia Market Outlook (7 major markets)
16. Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia Access and Reimbursement Overview
17. KOL Views on the Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia Market.
18. Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia Market Drivers
19. Hospital-Acquired & Ventilator-Associated Bacterial Pneumonia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings:
https://www.delveinsight.com/sample-request/hospital-acquired-and-ventilator-associated-bacterial-pneumonia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.